CD274 and neoplasm: This study indicated that the TNT regimen—comprising LCRT, mFOLFOX6 chemotherapy, and a PD-L1 inhibitor—resulted in a favorable complete tumor response rate with acceptable tolerability, offering a potential treatment option for organ preservation in patients with pMMR/MSS low RC.